These include monotherapy blockade of programmed cell death 1 (PD‐1) in patients with programmed cell death ligand 1 (PD‐L1) tumor proportion score (TPS) of 50% or greater,2 or combination with anti‐PD‐(L)1 antibody plus chemotherapy, irrespective of tumor PD‐L1 expression. The gene discussed is PDCD1; the disease is neoplasm.